Results 81 to 90 of about 258,109 (297)

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Associations of exposure to acrylamide and glycidamide with psoriasis among adults: Findings from a population-based study

Ecotoxicology and Environmental Safety
Acrylamide (AA), a hazardous chemical prevalent in the environment and human diet, and its metabolite glycidamide (GA) are suspected contributors to psoriasis.
Rui Ma, Nan Yang, Hao Mei, Yu Zhuang, Yu Wang, Yuanyuan Wang, Xin Wang, Yuling Shi   +7 more
doaj   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis [PDF]

, 2004
Background: Patient reported outcome measures used in studies of psoriatic arthritis (PsA) have been found to be inadequate for determining the impact of the disease from the patient’s perspective.
Doward, L.C., Emery, P., McKenna, S.P., Tennant, A., Veale, D.J., Whalley, D.   +5 more
core   +2 more sources

PEPITEM Regulates the Synovial Microenvironment During Immune‐Mediated Inflammatory Arthritis to Limit Disease

Arthritis &Rheumatology, EarlyView.
Objective Here we investigate the status of the adiponectin–PEPITEM pathway in early, treatment naive rheumatoid arthritis (RA) and psoriatic arthritis (PsA) and the therapeutic efficacy of PEPITEM administration in preclinical models. Methods Peripheral blood was isolated from patients with clinical suspect arthralgia and suspected inflammatory ...
Mussarat Wahid, Samuel Kemble, Oladimeji Abudu, Anella Saviano, Christopher Mahony, Jonathan W. Lewis, Thomas A. Nicholson, Anna Schettino, Noemi Marigliano, Kathryn Frost, Jenefa Begum, Alyssa M. Urbanowski, Marion Limo, Rakesh Jha, Sandra Martinez Jarquin, Laleh Pezhman, Abbie E. A. Degan, Amy E. Anderson, Charlotte G. Smith, Armaiti Batki, Holly Adams, Francesco Caso, Raffaele Scarpa, Iain McInnes, Stefan Siebert, Arthur G. Pratt, Andrew Filer, Karim Raza, Adam P. Croft, Myriam Chimen, Felicity de Cogan, G. Ed Rainger, Asif J. Iqbal, Francesco Maione, Helen M. McGettrick   +34 more
wiley   +1 more source

Positive associations between triglyceride-glucose (TyG) and TyG-body mass index (TyG-BMI) with cardiovascular disease in patients with psoriasis: cross-sectional results from the SPEECH

Frontiers in Immunology
BackgroundPatients with psoriasis have an increased risk of developing cardiovascular disease(CVD), yet reliable potential markers for cardiovascular risk assessment remain insufficient.
Ying Li, Ying Li, Dawei Huang, Dawei Huang, Biao Ma, Biao Ma, Yuxiong Jiang, Yuxiong Jiang, Bo Yu, Bo Yu, Jianfeng Zheng, Jianfeng Zheng, Yangfeng Ding, Yangfeng Ding, Yuling Shi, Yuling Shi   +15 more
doaj   +1 more source

Ustekinumab for the treatment of psoriatic arthritis: an update. [PDF]

, 2014
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic ...
Davari, Parastoo, Fazel, Nasim, Kamangar, Faranak, Leo, Michael S   +3 more
core   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola, Philip Mease, Alan Kivitz, Naveed Sattar, Laura C. Coates, Daniel Aletaha, Cynthia E. Kartman, Peter Fischer, Luna Sun, Píndaro Martínez‐Osuna, Andris Kronbergs, Purvi Prajapati, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +14 more
wiley   +1 more source

Botulinum Toxin A in Treatment of Facial Flushing

Acta Medica Iranica, 2016
Flushing is a condition with episodic attacks of redness of the skin with a sensation of warmth or burning, this disease causes emotional and functional problems in patients.
Gholamreza Eshghi, Leila Khezrian, Pedram Alirezaei   +2 more
doaj